Recently, Compass Pathways issued a press release stating “that it has been granted US Patent No 10,519,175 (“the ‘175 patent”), relating to methods of treating drug-resistant depression with a psilocybin …
The psilocybin field is underdeveloped. Only one active ingredient in “magic mushrooms” has been formulated and studied in a meaningful way.
The pharmaceutical industry has failed to create safe and effective chemical compositions for treating mood disorders, such as depression, anxiety, compulsion, addiction, etc.
The psilocybin field needs to shift its focus from “magic mushrooms” to the active molecules within them.
We can make better products for treating mood disorders by formulating naturally occurring psilocybin derivatives.